ArticleInternational urology and nephrology2026
177Lu-vipivotide tetraxetan (PSMA-617) vs cabazitaxel in metastatic castration-resistant prostate cancer: a real-world analysis using the TriNetX database.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
177Lu-vipivotide tetraxetan prostate-specific membrane antigen (177Lu-PSMA-617) has shown promising results in clinical trials for patients with metastatic castration-resistant prostate cancer (mCRPC). However, real-world data comparing 177Lu-PSMA-617 to other third-line agents, such as cabazitaxel, is sparse. Using the TriNetX database, we identified patients aged ≥ 18 with mCRPC from 1/1/2010 to 12/31/2024. Patients were stratified into four groups: Group 1A (Docetaxel → Abiraterone/androgen receptor inhibitor [ARI] → 177Lu-PSMA-617), Group 1B (Docetaxel → Abiraterone/ARI → Cabazitaxel), Group 2A (Abiraterone/ARI → Docetaxel → 177Lu-PSMA-617), and Group 2B (Abiraterone/ARI → Docetaxel → Cabazitaxel). Propensity score matching (1:1) was performed to adjust for confounding variables, and outcomes were evaluated using risk assessments and Kaplan-Meier survival analyses. Of 77,649 patients with mCRPC, 170 were identified in Group 1A, 754 in 1B, 233 in 2A and 851 in Group 2B. Primary outcomes included overall survival at 1, 2, and 3 years, with secondary outcomes assessing rates of anemia, fatigue, neutropenia, and dry mouth. Kaplan-Meier analyses revealed significantly improved survival in the 177Lu-PSMA-617 groups, with 3-year survival rates of 21.6% (1A) and 28.5% (2A) compared to 16.3% (1B) and 10.7% (2B) in the cabazitaxel groups (p < 0.0001). 177Lu-PSMA-617 was also associated with a more favorable toxicity profile, with reduced rates of anemia and fatigue. However, dry mouth was more frequent, although these toxicity findings should be interpreted cautiously given the event rarity. These survival benefits were consistent with mean PSA reductions observed in the 177Lu-PSMA-617 groups, further supporting its efficacy. Our real-world analysis demonstrates that 177Lu-PSMA-617 significantly improves survival and has a more favorable safety profile compared to cabazitaxel in mCRPC. These findings support its role as a preferred third-line option. However, further large-scale studies are needed to validate these findings in broader patient populations and explore long-term outcomes.
Indexed as
Identifiers
40991193What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.